277 related articles for article (PubMed ID: 19022220)
21. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
[TBL] [Abstract][Full Text] [Related]
22. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
23. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
24. Suppression of human hepatoma growth in vivo by a monoclonal antibody against a Mr 45,000 protein.
Lin Y; Feng J; Yang D; Shen Y; Yan X
Cancer Invest; 2006 Dec; 24(8):734-9. PubMed ID: 17162555
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
26. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Feng M; Gao W; Wang R; Chen W; Man YG; Figg WD; Wang XW; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2013 Mar; 110(12):E1083-91. PubMed ID: 23471984
[TBL] [Abstract][Full Text] [Related]
27. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
Umezu T; Shibata K; Shimaoka M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Senga T; Kikkawa F
Cancer Sci; 2010 Jan; 101(1):143-8. PubMed ID: 19860840
[TBL] [Abstract][Full Text] [Related]
28. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
29. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
30. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
32. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
33. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
34. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3 antibodies: a new therapeutic target for liver cancer.
Feng M; Ho M
FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
[TBL] [Abstract][Full Text] [Related]
36. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
[TBL] [Abstract][Full Text] [Related]
37. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
38. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
40. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]